Epidemiology and antibiotic resistance of prosthetic joint infections according to time of occurrence, a 10-year study.


Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
11 2022
Historique:
received: 23 11 2021
revised: 03 07 2022
accepted: 08 07 2022
pubmed: 7 8 2022
medline: 19 10 2022
entrez: 6 8 2022
Statut: ppublish

Résumé

To describe the microorganisms responsible for prosthetic joint infections (PJIs) and their antimicrobial susceptibilities, and to propose appropriate empirical antimicrobial treatments (EATs) according to time of occurrence METHODS: This 10-year retrospective study presents the bacterial etiology of 282 consecutive PJIs in a French hospital according to time of occurrence (adapted from Zimmerli's classification: early, <3 months; delayed, 3-12 months; late acute, >12 months with hematogenous seeding or contiguous spread; late chronic, >12 months without hematogenous seeding). The expected efficacy of various EATs was analyzed for each PJI. Staphylococci were the most commonly found bacteria (S. aureus (44.3%), coagulase-negative staphylococci (25.2%) with 15.2% and 49.3% methicillin resistance, respectively), followed by Gram-negative bacilli (GNB) (17.7%) and streptococci (14.9%). The distribution of species varied between categories, but antibiotics targeting GNBs were required in all categories. Imipenem-vancomycin was the most effective combination (99.3%) but should be reserved for patients with suspected resistant GNB. Cefotaxime-vancomycin was less effective in early/delayed and late PJIs (91.1% and 86.1%, respectively), due to resistant GNB and polymicrobial infections. Piperacillin/tazobactam-vancomycin appeared to be appropriate in all situations (>96% efficacy). Proposing universal recommendations remains challenging, but a good understanding of the local epidemiology is important for optimizing EATs.

Identifiants

pubmed: 35933039
pii: S0163-4453(22)00417-0
doi: 10.1016/j.jinf.2022.07.009
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Coagulase 0
Vancomycin 6Q205EH1VU
Imipenem 71OTZ9ZE0A
Cefotaxime N2GI8B1GK7
Tazobactam SE10G96M8W
Piperacillin X00B0D5O0E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

492-498

Informations de copyright

Copyright © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alice Casenaz (A)

Department of Bacteriology, Dijon Bourgogne University Hospital, BP 37013, Dijon Cedex 21070, France.

Lionel Piroth (L)

Infectious Diseases Department, Dijon Bourgogne University Hospital, 14 rue Paul Gaffarel, Dijon 21079, France; INSERM, CIC1432, Clinical Epidemiology Unit, Dijon Bourgogne University Hospital, Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, Dijon, France.

Ludovic Labattut (L)

Department of Orthopaedic Surgery, Dijon University Hospital, CHU Dijon, 14 rue Paul Gaffarel, Dijon Cedex 21079, France.

Thibault Sixt (T)

Infectious Diseases Department, Dijon Bourgogne University Hospital, 14 rue Paul Gaffarel, Dijon 21079, France.

Arnaud Magallon (A)

Department of Bacteriology, Dijon Bourgogne University Hospital, BP 37013, Dijon Cedex 21070, France; UMR/CNRS 6249 Chrono-Environnement, University of Bourgogne-Franche-Comté, Besançon, France.

Adrien Guilloteau (A)

Methodological Support Unit, Dijon University Hospital, CHU Dijon, 14 rue Paul Gaffarel, Dijon Cedex 21079, France.

Catherine Neuwirth (C)

Department of Bacteriology, Dijon Bourgogne University Hospital, BP 37013, Dijon Cedex 21070, France; UMR/CNRS 6249 Chrono-Environnement, University of Bourgogne-Franche-Comté, Besançon, France.

Lucie Amoureux (L)

Department of Bacteriology, Dijon Bourgogne University Hospital, BP 37013, Dijon Cedex 21070, France; UMR/CNRS 6249 Chrono-Environnement, University of Bourgogne-Franche-Comté, Besançon, France. Electronic address: lucie.amoureux@chu-dijon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH